ActiGraftPro® (Product Number RD2301) is an FDA-cleared, advanced biologic wound management system optimized for Hospital Outpatient Departments (HOPD) and clinical environments. The system transforms a small, 18–20 mL sample of a patient's own peripheral whole blood into an active, living blood clot scaffold directly at the bedside in five minutes or less.

Unlike traditional Platelet-Rich Plasma (PRP) systems that strip away red and white blood cells, ActiGraftPro preserves the blood's entire cellular matrix—including fibrin, red blood cells, white blood cells, platelets, and essential cytokines—to replace the dysfunctional extracellular matrix of chronic, stalled wounds.

• No Capital Equipment Required: Completely eliminates centrifuge dependency, meaning zero equipment to purchase or maintain.
• Completely Autologous Care: Created solely from the patient’s blood, containing zero bovine, porcine, or placental tissue.
• Versatile Sizing & Placement: A single kit produces a 28 cm² clot, safe for irregular wounds and exposed bone or tendon.
• Clinically Proven Efficacy: Backed by peer-reviewed data, boasting a 72% complete wound closure rate within 12 weeks.
• Streamlined Facility Billing: Outpatient facility settings utilize dedicated reimbursement pathways under HCPCS Billing Code G0465.